Victory Capital Boosts Stake in AbbVie

Investment firm increases holding in pharmaceutical company by 8.6% in Q3

Mar. 3, 2026 at 8:39am

Got story updates? Submit your updates here. ›

Victory Capital Management Inc. has increased its stake in AbbVie Inc. (NYSE:ABBV) by 8.6%, adding 120,490 shares in the third quarter. The firm now owns 1,525,632 shares of the pharmaceutical company's stock, valued at $350,656,000.

Why it matters

This investment move by Victory Capital, a major institutional investor, signals continued confidence in AbbVie's long-term growth potential. As a leading biopharmaceutical company, AbbVie's performance is closely watched by the investment community.

The details

According to the filing with the Securities & Exchange Commission, Victory Capital purchased the additional 120,490 shares of AbbVie during the third quarter. This increased the firm's total stake in the company to approximately 0.09% of the outstanding shares.

  • Victory Capital disclosed the increased stake in AbbVie in a filing on March 3, 2026.

The players

Victory Capital Management Inc.

A global investment management firm that oversees over $150 billion in client assets.

AbbVie Inc.

A research-driven biopharmaceutical company that focuses on discovering, developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Victory Capital's increased stake in AbbVie underscores the pharmaceutical company's appeal to major institutional investors. As AbbVie continues to advance its drug pipeline and navigate industry challenges, its performance will likely remain a focus for the investment community.